- Home
- KRYS vs ACLX Comparison
KRYS vs ACLX Comparison
Compare KRYS & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRYS
- ACLX
- Stock Information
- Founded
- KRYS 2015
- ACLX 2015
- Country
- KRYS United States
- ACLX United States
- Employees
- KRYS N/A
- ACLX N/A
- Industry
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- KRYS Health Care
- ACLX Health Care
- Exchange
- KRYS Nasdaq
- ACLX Nasdaq
- Market Cap
- KRYS 4.3B
- ACLX 4.1B
- IPO Year
- KRYS 2017
- ACLX 2022
- Fundamental
- Price
- KRYS $144.86
- ACLX $77.84
- Analyst Decision
- KRYS Strong Buy
- ACLX Strong Buy
- Analyst Count
- KRYS 10
- ACLX 13
- Target Price
- KRYS $204.90
- ACLX $114.75
- AVG Volume (30 Days)
- KRYS 268.2K
- ACLX 538.2K
- Earning Date
- KRYS 11-03-2025
- ACLX 11-06-2025
- Dividend Yield
- KRYS N/A
- ACLX N/A
- EPS Growth
- KRYS 36.22
- ACLX N/A
- EPS
- KRYS 4.91
- ACLX N/A
- Revenue
- KRYS $359,205,000.00
- ACLX $56,979,000.00
- Revenue This Year
- KRYS $34.33
- ACLX N/A
- Revenue Next Year
- KRYS $47.84
- ACLX $174.18
- P/E Ratio
- KRYS $29.46
- ACLX N/A
- Revenue Growth
- KRYS 116.08
- ACLX N/A
- 52 Week Low
- KRYS $122.80
- ACLX $47.86
- 52 Week High
- KRYS $207.84
- ACLX $107.37
- Technical
- Relative Strength Index (RSI)
- KRYS 48.61
- ACLX 69.25
- Support Level
- KRYS $136.73
- ACLX $70.11
- Resistance Level
- KRYS $152.96
- ACLX $73.10
- Average True Range (ATR)
- KRYS 4.68
- ACLX 2.49
- MACD
- KRYS -0.69
- ACLX 0.66
- Stochastic Oscillator
- KRYS 50.09
- ACLX 95.72
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.